Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.

@article{Gregorc2008GermlinePI,
  title={Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.},
  author={Vanesa Gregorc and Maartje Hidalgo and Anna Spreafico and George Cusatis and Vienna Ludovini and Roxann G. Ingersoll and Sharon Marsh and Seth Steinberg and Maria Grazia Vigan{\`o} and Domenico Ghio and Eugenio Villa and Alex Sparreboom and Sharyn D. Baker},
  journal={Clinical pharmacology and therapeutics},
  year={2008},
  volume={83 3},
  pages={477-84}
}
The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation and overall survival in white patients with non-small-cell lung cancer (NSCLC) treated with the EGFR tyrosine kinase inhibitor, gefitinib. Of 175 consecutive patients treated with oral gefitinib (250 mg/day), 170 (median age: 67 years; 72% men) were evaluable for genotyping and survival. Fifty-five patients (33%) had stable disease and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…